

# San Francisco

## Spring Group Meeting

# SPECIALS

Symptom Management & Survivorship  
Committee

# Symptom Management & Survivorship Committee

## Leadership

Co-Chairs: ..... Michael J. Fisch, MD, MPH  
 ..... Norah Lynn Henry, MD, PhD

## Time/Location

Thursday, May 1, 2025 2:00 p.m. - 4:00 p.m.  
 Room: Bayview Room (Bay Level)

## Agenda

### Plenary

Symptom Management and Survivorship from the Lens of an Oncologist and Cancer Survivor - Mark Lewis, MD, Intermountain Healthcare

**Patient Advocate Update** - Lee Jones

### Concepts in Development

**S2423**, "Testing the Fatigue Diet in People with Early-Stage Breast Cancer: The GUIDE Study". Drs. S. Zick and H. Greenlee. Triage informally reviewed on 1/22/24. R01 application submitted February 8th. Scored a 38 in the 36th percentile, plan to resubmit R01 in November 2024.

**S2435**, "Phase III Trial of an App-Supported Sleep Coaching Intervention in Post-Treatment Survivors of Diverse Cancers and their Bedroom Partners". Drs. Rina Fox and Terry Badger. R01 submitted June 5th. Review response expected Q4 2024. Summary statements received, planning to resubmit in June 2025.

Use of GLP-1 agonists in early stage breast cancer survivors. Dr. Vidhya Nair

Weight management prior to radical prostatectomy to improve quality of life and obesity-driven prostate cancer biomarkers. Dr. Jill Hamilton-Reeves

Observational cohort study of cancer-related cognitive dysfunction in men with prostate cancer on ADT-based regimens. Dr. Clara Hwang

Exercise intervention to reduce fatigue in men with prostate cancer on ADT-based regimens. Drs. Lisa Rogers and Dennis Kerrigan

The Use of Memantine for the Prevention of Cancer-Related Cognitive Impairment (CRCI) in Young Adult (YA) Patients with Colorectal Cancer. Dr. Christopher Cann

### Active Studies

**S2013**, "Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study." Drs. Gunturu, Hershman, Kuderer, et al. Activated: 8/16/21; Temporarily closed to accrual: 5/6/24.

**S2205**, "ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy." Drs. Accordino, Pennington, Hershman, et al. Activated: 3/16/23.

### Closed Studies

**S1600**, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune)." Drs. Hamilton-Reeves, Holzbeierlein, Kukreja, et al. Permanently closed 10/20/23.

**S1614**, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang, Lok, Gehring, et al. Permanently closed 11/15/22.

**S1714**, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi, Hershman, Brannagan, et al. Activated: 3/1/19; Permanently closed 11/15/21.

**S1706**, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Dr. Jaggi. Activated: 9/12/18; Closed to accrual: 7/1/24.

**S1806**, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Dr. Singh. Activated: 4/19/18; Closed to accrual: 4/1/24.

**S1826**, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age  $\geq$  12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera, Friedberg. Activated: 7/19/19; Closed to accrual: 12/1/22.

**S0820**, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. Zell, Brown, Lance, et al. Activated: 3/1/13; Closed to accrual: 6/30/23.

**S1904**, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, Kukafka, Hershman, et al. Activated: 9/1/20; Closed to accrual: 6/14/24.



# Symptom Management & Survivorship Committee

**S2010**, “A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN).” Drs. Henry, Hershman, and Skaar. Activated: 1/17/23; Closed to accrual: 1/15/25.

## Committee Business

1. What other studies are we planning?
2. What is happening with our open studies?
3. What other updates should we know about?
  - Patient Advocate Update
  - Statistical Center Update

## Other SWOG Studies with Symptom Control and QOL Component

### Cancer Care Delivery

**S1703**, “Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer.” Drs. Accordino, Hershman, and Ramsey. Activated: 7/16/18.

**S1912CD**, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Drs. Shankaran, Carlos, Hershman, et al. Activated: 7/26/21.

**S2108CD**, “A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy.” Drs. Reuter, Trivedi, Symington, et al. Activated: 8/22/22.

### GU

**S1802**, “Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.” Dr. Chapin. Activated: 9/17/18.

### Leukemia

**S1925**, “Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients

with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.” Drs. Stephens, Hill, Pagel, et. al. Activated: 12/14/20.

### Lung

**S1914**, “A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC.” Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

**S1827**, “MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).” Drs. Rusthoven, Brown, Wefel, et al. Activated: 1/10/20.

### Lymphoma

**S1918**, “A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.” Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

### Myeloma

**S1803**, “Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study).” Drs. Krishnan, Chhabra, and Callander. Activated: 6/27/19.

### NCTN Studies

**CTSU/NRG-GI004**, “Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/ Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.” Dr. Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21.

# Symptom Management & Survivorship Committee

## Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

### Published/Accepted Manuscripts

**S2010** Active symptom monitoring for premenopausal women with breast cancer initiating adjuvant endocrine therapy: Protocol for the SWOG S2010 randomized controlled efficacy trial. Henry NL, Unger J, Darke A, Skaar T, Fisch M, Hershman D. Contemp Clin Trials. Dec;147:107712, 2024. <https://pubmed.ncbi.nlm.nih.gov/39395534/>

**Multiple Studies\*** Neighborhood Socioeconomic Deprivation and Patient-Reported Outcomes in Symptom Management Trials for Breast Cancer Patients. Vaidya R, Till C, Henry NL, Fisch M, Hershman D, Unger J.. Breast Cancer Res Treat Feb;209(3):603-611, 2025. [\*S0927,S1200,S1202] <https://pubmed.ncbi.nlm.nih.gov/39560823/>

### Submitted Manuscripts

**S1714** A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Patients with Cancer: SWOG S1714. Trivedi M, Unger J, Darke A, Hertz D, Brannagan T, Smith S, Hershman D, Henry NL, Fisch M. Submitted.

# Symptom Management & Survivorship Committee

**Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study**

	S1600	S2010	S2013	S2205	A211901	A221805	A222001	A222004
Audie L Murphy VA Hospital	-	-	26	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	1	-	-
Banner University Medical Center - Tucson	-	-	5	-	-	-	1	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	5	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer CenterLAPS	-	-	-	-	-	4	-	-
Cancer Research Consortium of West Michigan NCORP	-	2	-	1	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	12	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	4	131	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	1	17	-	-	-	-	-
City of Hope Comprehensive Cancer Center	6	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	25	27	28	-	-	-	1
Columbus NCI Community Oncology Research Program	-	-	35	-	-	-	-	-
CommonSpirit Health Research Institute	-	13	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	1	-	-
Fred Hutchinson Cancer Research Center LAPS	13	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	22	-	-	-	-	-
Georgia NCI Comm Oncology Research Program	-	20	67	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	9	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	4	25	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	9	4	12	-	-	-	-
Heartland Cancer Research NCORP	-	25	234	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	29	-	-	-	-	-
Henry Ford Hospital	8	-	-	2	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	22	13	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	-	24	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	27	74	-	-	-	-	-
Lahey Hospital & Medical Center	-	12	63	-	-	-	-	-
Massachusetts Vets Epidemiology Research and Information Center	-	-	63	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	9	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	19	1	-	-	-	-	-
Moffitt Cancer Center	-	9	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	7	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-
NCORP of the Carolinas	-	-	-	-	-	-	-	-

# Symptom Management & Survivorship Committee

**Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study**

	S1600	S2010	S2013	S2205	A211901	A221805	A222001	A222004
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	3
New Mexico Minority Underserved NCORP	-	20	-	17	-	-	-	-
Northwestern University LAPS	-	7	-	-	-	-	-	-
Oregon Health & Science University	-	-	12	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	11	2	-	-	-	-	-
Rhode Island Hospital	-	-	-	7	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	18	55	-	7	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	3	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	148	48	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	-	-	-
The Don & Sybil Harrington Cancer Center	-	10	4	-	-	-	-	1
UC Davis Comprehensive Cancer Center LAPS	-	7	13	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	6	-	-	-	-	-
UC San Diego Moores Cancer Center	-	2	2	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	4	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	78	-	12	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	-	4	22	-	-	-	-	-
U of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-	3	-	-	-	-
University of Arkansas for Medical Sciences	-	6	25	-	-	-	-	-
University of Colorado Cancer Center LAPS	14	3	38	-	-	2	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	51	18	82	17	1	2	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	32	-	-	-	-	-	-
University of Mississippi Medical Center	-	1	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	2	-	-	-	-	-	-
University of Rochester LAPS	16	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	17	53	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	3	-	5	-	1	2
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	13	-	-	-	-
Western States Cancer Research NCORP	-	-	-	4	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	8	27	-	-	-	-	-
ALLIANCE	5	39	352	49	-	-	-	-
ECOG-ACRIN	4	34	110	5	-	-	-	-
NRG	2	85	256	68	-	-	-	-
<b>Total</b>	<b>203</b>	<b>547</b>	<b>2,098</b>	<b>274</b>	<b>13</b>	<b>10</b>	<b>2</b>	<b>7</b>

# Symptom Management & Survivorship Committee

**Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study**

	ACCL1931	EAQ202	NRGCC010	NRGCC011
Audie L Murphy VA Hospital	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	-	-	-	1
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-
Columbus NCI Comm Oncology Research Program	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	1
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-
Georgia NCI Comm Oncology Research Program	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	11	-
Hawaii Minority Underserved NCORP	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-
Henry Ford Hospital	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	-
Lahey Hospital & Medical Center	-	-	-	4
Massachusetts Vets Epidemiology Research & Information Cntr	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-
Moffitt Cancer Center	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-
Mount Sinai Hospital	-	-	-	1
NCORP of the Carolinas	-	39	-	-

# Symptom Management & Survivorship Committee

**Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study**

	ACCL1931	EAQ202	NRGCC010	NRGCC011
Nevada Cancer Research Foundation NCORP	-	4	-	-
New Mexico Minority Underserved NCORP	-	-	-	-
Northwestern University LAPS	-	-	-	-
Oregon Health & Science University	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-
Rhode Island Hospital	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-
Salem Hospital	-	-	-	6
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
Stanford Cancer Institute Palo Alto	2	-	-	-
The Don & Sybil Harrington Cancer Center	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	2
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
Universidad de la Republica - Facultad de Medicina	-	-	-	-
U of Alabama at Birmingham/Deep S Research Consortium LAPS	-	-	-	-
U of Arkansas for Medical Sciences	-	-	-	-
U of Colorado Cancer Center LAPS	-	-	-	-
U of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	8
U of Kentucky/Markey Cancer Center	-	-	-	3
U of Michigan Comprehensive Cancer Center LAPS	-	-	-	-
U of Mississippi Medical Center	-	-	-	-
U of Oklahoma Health Sciences Center LAPS	-	-	2	-
U of Rochester LAPS	-	-	-	-
U of Texas Health Science Center at San Antonio	-	-	-	-
U of Utah - Huntsman Cancer Institute LAPS	-	-	-	-
Upstate Carolina NCORP	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-
ALLIANCE	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
<b>Total</b>	<b>2</b>	<b>43</b>	<b>13</b>	<b>26</b>



